Evidence map›Paper›PMID 21217145›Full record

ArticleProtein engineering, design & selection : PEDS2011

Conversion of scFv peptide-binding specificity for crystal chaperone development.

Jennifer C Pai, Jeffrey A Culver, Jason E Drury, Rakesh S Motani, Raquel L Lieberman, Jennifer A Maynard

Open access · bronzeAbstract read
In one paragraph

Article in Protein engineering, design & selection : PEDS, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Increased Fab thermoresistance via VH-targeted directed evolution.Protein engineering, design & selection : PEDS · 2015
    Article
  3. Article
  4. Article
  5. Antibody-enabled small-molecule drug discovery.Nature reviews. Drug discovery · 2012
    Review
  6. Article
  7. Article
  8. Review
  9. Antibody fragments as tools in crystallography.Clinical and experimental immunology · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jennifer C PaiDepartment of Chemical Engineering, University of Texas at Austin, TX 78712, USA.
Jeffrey A Culver
Jason E Drury
Rakesh S Motani
Raquel L Lieberman
Jennifer A Maynard
Georgia Institute of Technology · USThe University of Texas at Austin · USUniversity of Minnesota · US

Funding

Returning to the workforce supplement request for R01 GM095638R01GM095638 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI MAYNARD, JENNIFER A · 2010 to 2014
$1.3M
Antibody-mediated protection against whooping coughR21AI066239 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI MAYNARD, JENNIFER A · 2005 to 2006
$402k
NCI NIH HHS Y1-CO-1020NIAID NIH HHS AI066239NIAID NIH HHS R21 AI066239NIGMS NIH HHS R01 GM095638NIGMS NIH HHS Y1-GM-1104
6 · The paper itself

Abstract

In spite of advances in protein expression and purification over the last decade, many proteins remain recalcitrant to structure determination by X-ray crystallography. One emerging tactic to obtain high-quality protein crystals for structure determination, particularly in the case of membrane proteins, involves co-crystallization with a protein-specific antibody fragment. Here, we report the development of new recombinant single-chain antibody fragments (scFv) capable of binding a specific epitope that can be introduced into internal loops of client proteins. The previously crystallized hexa-histidine-specific 3D5 scFv antibody was modified in the complementary determining region and by random mutagenesis, in conjunction with phage display, to yield scFvs with new biochemical characteristics and binding specificity. Selected variants include those specific for the hexa-histidine peptide with increased expression, solubility (up to 16.6 mg/ml) and sub-micromolar affinity, and those with new specificity for the EE hexa-peptide (EYMPME) and nanomolar affinity. Complexes of one such chaperone with model proteins harboring either an internal or a terminal EE tag were isolated by gel filtration. The 3.1 Å resolution structure of this chaperone reveals a binding surface complementary to the EE peptide and a ∼52 Å channel in the crystal lattice. Notably, in spite of 85% sequence identity, and nearly identical crystallization conditions, the engineered scFv crystallizes in a different space group than the parent 3D5 scFv, and utilizes two new crystal contacts. These engineered scFvs represent a new class of chaperones that may eliminate the need for de novo identification of candidate chaperones from large antibody libraries.

Indexed as

Antibody SpecificityAmino Acid SequenceComplementarity Determining RegionsCrystallizationCrystallography, X-RayEpitopesHistidineHumansModels, MolecularMolecular ChaperonesMolecular Sequence DataOligopeptidesPeptide LibraryPeptidesProtein ConformationProtein EngineeringComplementarity Determining RegionsEpitopesHis-His-His-His-His-HisHistidineMolecular ChaperonesOligopeptidesPeptide LibraryPeptidesSingle-Chain Antibodies

Identifiers

PMID21217145
PMCPMC3077810
OpenAlexW2100463775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.